Recent data have proposed that transcription of the KAI1 metastasis suppressor gene is directly mediated by p53 and that loss of KAI1 expression in advanced prostate cancer is simply due to loss of p53 function after mutation. To investigate this possibility, we have examined KAI1 mRNA (by in situ hybridisation) and p53 protein expression (by immunohistochemistry) as an indicator of wildtype or mutant p53, in a series of 77 paraffin-embedded prostate tissue samples, including post-mortem normal prostates (2), benign prostatic hyperplasia (10), localised cancer (grades 4-6, 25; grades 7-9, 21) and prostate-derived bony metastases (19). Overall, we confirmed that expression of KAI1 mRNA decreased from normal tissue, through localised cancer to bony metastases (P ¼ 0.055, tending to significance), while levels of p53 staining significantly increased with cancer progression (P ¼ 0.046). These were consistent with the possibility that loss of p53 function might be responsible for loss of KAI1 mRNA. However, by close examination of KAI1 and p53 in adjacent tissue sections, we found no correlation between decreased levels of KAI1 mRNA and overexpression of p53 protein (P ¼ 0.497). In addition, high levels of KAI1 mRNA could be identified in samples irrespective of p53 staining. Our data suggest that mutation of p53 is independent of the loss of KAI1 mRNA, and do not support a role for p53 in regulating the expression of KAI1.
Introduction
The protein encoded by the KAI1 gene on chromosome 11p11.2 belongs to the TM4 superfamily of proteins and is involved in maintenance of cell-extracellular matrix and cell-cell interactions. 1 Loss of KAI1 expression results in increased invasive and metastatic behaviour in tumour cell lines, [2] [3] [4] [5] indicating that KAI1 may function as a metastasis suppressor. Consistent with this role, several studies have provided convincing evidence of reduced KAI1 expression associated with invasive and metastatic stages of many different tumour types, including lung, 6 bladder, 7 liver, 8 breast 9 and colon cancers. 10 Loss of KAI1 expression is also associated with a poor prognosis in several cancer types 6, 11, 12 and breast cancer recurrence. 13 The role of KAI1 in prostate cancer progression has been studied by several groups; indeed KAI1 was initially proposed to be a prostate-specific metastasis suppressor. 1 While recent studies have provided some evidence that increased KAI1 expression might occur in early stage disease, 14 all studies thus far have shown that KAI1 mRNA and protein levels are dramatically reduced in advanced disease, as well as in lymph node metastases. 1, [15] [16] [17] Spread to the lymph nodes is common in prostate cancer but metastasis to bone also occurs with high frequency (475% patients 18, 19 ). If this happens and the cells develop hormone independence, the disease is essentially incurable and intensely painful. Analysis of KAI1 expression in prostate metastases in the bone remains to be determined.
The underlying basis for loss of KAI1 expression in prostate and other cancers is still not understood. [20] [21] [22] [23] However, preliminary evidence suggests that transcription of the KAI1 gene might be directly regulated by p53, 24 leading to the hypothesis that a loss of KAI1 expression in Prostate tumours is directly due to a loss of p53 function. This is an attractive idea directly linking a commonly mutated gene in prostate cancer (p53 25 ) with a metastasis suppressor gene. In order to obtain evidence in support of this model, we have examined KAI1 mRNA (by in situ hybridisation) and p53 protein (by immunohistochemistry) expression in a series of normal, benign and malignant prostate tissues, including localised tumours and bony metastases. Our data confirm that a loss of KAI1 mRNA expression occurs in prostate cancer progression, including bony metastases but there is no correlation between this change and p53 overexpression.
Materials and methods

Tumor samples
A series of 77 paraffin-embedded prostate tissue samples were analysed, including two normal prostates (with no evidence of cancer) from post mortems (males of 26 and 56 y of age), 10 samples of benign prostate hyperplasia (BPH) and 46 samples of localised prostate cancer, 25 of Gleason grades 4-6 and 21 of Gleason grades 7-9, as well as 19 samples of prostate-derived bony metastases. All nonbony tissues had been routinely fixed in 10% buffered formaldehyde solution for more than 24 h, embedded in paraffin, and cut into 5-mm sections. Paraffin blocks of bony metastases were then surface decalcified using 0.5 M EDTA, rinsed and cut into 4-mm sections. This study was approved by the Research Ethics Committee of the South Eastern Sydney Area Health Service.
Transcription of digoxigenin-labelled KAI1 cRNA probes
A 1031 bp cDNA fragment encoding the full KAI1 cDNA was amplified from pCMVKAI1 1 and cloned into the EcoR1 site within the polylinker of Bluescript KS vector (Stratagene, La Jolla, CA, USA). After linearising with Xba1 (for antisense probes) or Xho 1 (for sense probes) digoxigenin (DIG)-labelled RNA probes were generated with a DIG RNA labelling kit (Boehringer Mannheim, Mannheim, Germany) using T3 (antisense) and T7 (sense) RNA polymerases, respectively. DIG-labelled probes were quantified by a dot-blot procedure according to the manufacturer's instructions (Boehringer Mannheim, Roche Molecular Biochemicals, Castle Hill, NSW, Australia).
In situ hybridisation
Sections were heated at 801C for 10 min in a humidified chamber (Hybaid Omnislide, Integrated Sciences, Teddington, UK) prior to dewaxing in xylene and rehydration in graded alcohol (100-50%), followed by immersion in diethylpyrocarbonate (DEPC)-treated water and 2Â standard sodium saline citrate (SSC). Slides were then placed in freshly prepared buffer (acetic anhydride, 250 ml/100 ml of 0.1 M triethanolamine hydrochloride with 0.9% NaCl) for 10 min at room temperature. Slides were then briefly rinsed in 2Â SSC and dehydrated through a graded series of alcohol (70-100%). Sections were immersed in chloroform for 5 min at room temperature, rehydrated to 70% ethanol, and allowed to air dry. After washing in 2Â SSC, slides were finally incubated in proteinase K (10-40 mg/ml) diluted in 0.1 M Tris-Cl pH 8.0 and 50 mM EDTA, for 10-30 min, and rinsed twice in 2Â SSC.
Staining of KAI1 in tissue sections using a digoxigenin (DIG)-labelled KAI1 riboprobe was performed as described in detail previously. 26 Briefly, a gene frame (Advanced Biotechnologies, Epsom, UK) was placed around each section. Hybridisation mixture (25 ml) containing hybridisation buffer consisting of 2 g dextran sulphate sodium salt (500 000 MW), in 4.8 ml water, 10 ml formamide, 4 ml 20Â SSC, 200 ml 100Â Denhardt's solution, 400 ml tRNA (25 mg/ml), 10 mg heparin sodium salt (155 USP/mg, Sigma), 800 ml sheared salmon sperm DNA (10 mg/ml), and 1 ml per 100 ml of buffer of 5 M dithiothreitol (DTT), and 25 ng/ml of either sense or antisense probe previously heated to 951C for 5 min, was applied to the sections, which were covered with appropriate coverslips and incubated overnight at 501C in a humidified chamber to allow hybridisation. Coverslips were then gently removed and slides washed four times in RNAse A buffer (20 mg/ml RNAse A in 25 ml 5 M NaCl, 2.5 ml of 1 M Tris-Cl pH 8.0, 50 ml 0.5 M EDTA) at 371C for 30 min to remove unhybridised singlestranded RNA, and then incubated at room temperature for 15 min in 2Â , 1Â and finally 0.5Â SSC all containing 10 mM DTT. After a stringent wash for 30 min at 551C in 0.1Â SSC, slides were washed twice in 2Â SSC at room temperature and blocked in 2% BSA, 2Â SSC and 0.3% Triton X-100 for 90 min at room temperature. Sections were then incubated overnight at 41C in this same blocking antibody containing antidigoxigenin antibody conjugated to alkaline phosphatase (1 : 500 dilution), washed twice in buffer I (0.1 M Tris-Cl pH 7.5, 0.1 M NaCl) and then twice in buffer II (0.25 M Tris-Cl pH 9.5, 0.1 M NaCl, 0.05 M MgCl 2 ). Detection was performed using a 4-nitro-blue tetrazolium salt (NBT, Boehringer Mannheim) and 5-bromo-4-chloro-3-indolyl-phosphate as substrates for the alkaline phosphatase according to the manufacturer's instructions. After colour development, slides were washed in buffer II, rinsed briefly in water, counterstained with nuclear fast red solution (Chroma IA 402, Lomb Scientific and Co., Sydney, Australia), rinsed with water and then in 70% ethanol. The slides were cover-slipped with appropriate mounting medium. Negative controls included the use of sense probe, treated with RNAse prior to hybridisation. The integrity of mRNA in each sample was verified using a b-actin probe.
Downregulation of KAI1 mRNA P Jackson et al Immunohistochemistry Paraffin-embedded tissues were stained for p53 using the PAb1801 monoclonal antibody (Novocastra Laboratories, Newcastle on Tyne, UK), as previously described. 7 Briefly, paraffin-embedded tissue sections were dewaxed in Histochoice Clearing Solution (Amresco, OH, USA), rehydrated in a graded series of ethanol (100, 95, 70 and 50%) and washed in distilled water. Sections were heated in a microwave oven for 10 min in antigen retrieval buffer (0.01 M disodium EDTA, 0.01 M trisodium citrate, 0.02 M Tris pH 8) and cooled for 15 min, then washed twice in PBS. This technique provided a clear background and high intensity of specific immunostaining. Endogenous peroxidase activity was quenched in 1.5% H 2 O 2 /PBS (Sigma, St Louis, MO, USA) for 15 min, followed by washing twice with PBS. Nonspecific protein binding was blocked in casein wash buffer (0.3% casein in 0.5% Tween 20/PBS) for 30 min. Sections were then incubated with primary antibodies overnight at 41C for p53, washed twice in 1 : 10 casein wash buffer for 5 min and incubated with 1 : 200 biotinylated antimouse IgG (Vector Laboratories, Burlingame, CA, USA) for 30 min. Specific intracellular immunoreactivity was detected by incubation with avidin-biotin/horseradish peroxidase complex (Vector Laboratories, Burlingame, CA, USA) for 45 min at room temperature, followed by colour development in 0.05% diamino-benzidine/0.01% H 2 O 2 /PBS pH 7.6 chromogen (Sigma, St Louis, MO, USA) for 5 min. Colour development was stopped by washing in distilled water and the section lightly counterstained in haematoxylin, dehydrated in a graded series of alcohol, cleared in xylene and finally mounted in Eukitt.
Scoring of immunohistochemistry and in situ hybridisation
Both immunochemistry and in situ hybridisation staining were assessed by an experienced pathologist (WD). Nuclear staining for p53 was assessed as follows: no observable staining (scored as p53-negative), and ! 0 to 2%; !2 to 5%; !5 to 20%; !20% immunoreactive nuclei (all scored as p53-positive). Within the !0 to 2% range, samples were also examined carefully for the presence of clusters of 12 or more immunoreactive nuclei with a 200 Â magnification field, 27 to ensure that samples were truly negative for p53 or if they contained small pockets of p53 positive cells. The locations of p53 positive and negative areas of the tumours were noted, and levels of KAI1 mRNA staining by in situ hybridisation assessed in the same area of a parallel section. Red staining was considered positive for KAI1 staining and the intensity of staining scored as 0, 1+, 2+ or 3+. Only those sections with an expression of KAI1 mRNA 41 were considered positive. Samples were thus scored as positive or negative.
Statistics
Differences in p53 protein and KAI1 mRNA staining among groups were analysed by a nonparametric Kruskal-Wallis test. Differences in staining between groups were tested by k 2 -analysis, and where the expected count was less than five, results were further assessed by Fisher's exact test. The possible relationship between p53 and KAI expression was analysed by k 2 -analysis of two-way frequency tables. Results were considered significant if Pr0.05 and the analysis was performed using SPSS/WIN 10A software.
Results
KAI1 mRNA and p53 protein expression in normal and tumourigenic prostate tissues
Consistent with observations from several previous studies, [15] [16] [17] there was an overall loss of KAI1 expression from normal tissue through primary cancer to metastases (data tending to significance with Kruskal-Wallis, k 2 ¼ 9.255; P ¼ 0.055). Positive staining for KAI1 mRNA was seen in all groups of tissues, but not in all cases in each group ( Figure 1 ; Table 1 ). It was highly expressed in the perinuclear areas of normal prostate luminol cells (arrow Figure 1b ; 2 of 2, 100%) and in BPH (arrow Figure 1d ; 7/10, 70%). Overall, a more diffuse distribution and much lower levels of expression were detected in primary cancers, and there was no observable difference between Gleason grades 4-6 (11/25, 44%) and 7-9 (arrow Figure 1f ; 9/21, 43%). Little expression was observed in bony metastases (arrow Figure 1h) , with only 4/19 (21%) showing detectable staining of KAI1 mRNA. KAI1 staining in metastases was also limited to fewer cells per section (average 20-40%), compared with the proportion of cells stained in normal, benign and localised tumours (average 60 to 480%). Positive nuclear staining of p53 protein followed a reverse trend to that seen for KAI1 mRNA, with a significant increase in staining from normal to localised tumour to metastases (Table 1 , Kruskal-Wallis, k 2 ¼ 9.688; P ¼ 0.046). No p53 staining was observed in normal samples (arrow Figure 1a) . Consistent with a recent review suggesting that mutation of p53 is an early event in prostate cancer, 28 similar levels of p53 overexpression were detected in both BPH (arrow Figure 1b Figure 1g ; 12/19; 63%). Interestingly, in benign and primary tumour groups, staining for p53 tended to be in small clusters of cells (average o10% of all cells), whereas in the bone metastases, the proportion of p53 overexpressing cells averaged 50% or more.
Taken together, our results are consistent with previous observations 15, 29 and indicate that expression of KAI1 generally decreases with prostate tumour progression, but that staining for p53 increases. These data are also consistent with the proposed relationship between p53 and KAI1 expressions. 24 This model predicts that high levels of KAI1 mRNA should be detected in prostate tissue in which immunohistochemical staining for p53 is low or absent (due to the presence of wild-type p53), but that KAI1 mRNA expression should be reduced Downregulation of KAI1 mRNA P Jackson et al Figure 1 Patterns of p53 protein (a, c, e, g) and KAI1 mRNA (b, d, f, h) expression in normal prostate and prostate tumour samples were assessed as described in Materials and methods. Immunohistochemical staining of p53 protein was absent from normal tissue (a), but present in low levels in both benign prostatic hyperplasia (c) and localised, primary tumours (e). Highest levels of staining were seen in bony metastases (g). High levels of KAI1 mRNA were detected in normal prostate (b) and benign prostatic hyperplasia (d), with overall, little or no staining detected in both primary tumours (f) and metastases (h). Insets show negative staining control using an isotype control antibody (immunohistochemistry) or sense RNA probe (in situ hybridisation). Arrows indicate typical staining pattern for p53 and KAI1. Magnification, Â 40.
Downregulation of KAI1 mRNA P Jackson et al or absent in tissues with high levels of p53 staining (due to stabilisation of mutant p53 protein).
Analysis of the relationship between KAI1 mRNA levels and p53 staining
We examined the relationship between KAI1 mRNA staining and p53 in our prostate tissue samples more closely, particularly looking at KAI1 mRNA staining in the small groups of p53-positive cells within tumour samples. We divided our 77 samples into four groups: (i) p53-negative and KAI1 mRNA-negative, (ii) p53-negative and KAI1 mRNA-positive, (iii) p53-positive and KAI1 mRNA-negative and (iv) p53-positive and KAI1 mRNA-positive. Results of this analysis are summarised in Table 2 , and show no correlation between p53 staining (and presumably p53 functional status) and KAI1 mRNA levels. Thus, KAI1 mRNA can be clearly seen in tissues that are either p53-negative or p53-positive (Table 3 
Discussion
Accumulating evidence has demonstrated that loss of KAI1 expression occurs in the invasive and metastatic stages of many cancer types, including prostate cancer; however, the underlying basis for this effect remains to be determined. In this study, we have examined the possibility that KAI1 expression might be regulated by p53, by analysing the relationship between KAI1 mRNA levels and p53 protein staining in a series of 77 prostate tissue specimens. Consistent with previous studies, 15, 16 we found that levels of KAI1 mRNA were progressively decreased, and p53 staining progressively increased, with tumour progression. In addition, we describe for the first time that loss of KAI1 expression occurs in bony metastases of prostate cancer. However, in all tissue types, we found no correlation between the presence and absence of p53 staining (and presumably wild-type or mutant p53) or KAI1 mRNA levels. While we cannot rule out a possibility that the PAbl 801 antibody used in the present study might not recognise all forms of mutant p53 protein, resulting in an underestimation of the proportion of tumour cells with mutant p53, and we acknowledge that specific p53 mutants within individual tumour cells were not identified, our conclusions are consistent with results of several recent studies, using different approaches, all of which have failed to find any supporting evidence for a direct relationship between p53 and KAI1. [30] [31] [32] Of particular relevance to this study, we have shown that there is no relationship between the presence of transcriptionally active wild-type p53 or specific transcriptionally inactive mutant p53 proteins and KAI1 levels, in a large series of prostate and bladder cancer cell lines. 30 Furthermore, transfection of cells with wild-type or mutant p53, the use of inducible p53 systems, the use of p53 inhibitors and agents that induce a p53-dependent response 31, 32 have all been unable to demonstrate evidence for a p53-dependent induction of KAI1 mRNA. Clearly, the KAI1 promoter contains a motif with homology to the consensus p53 binding motif, 24 but this does not necessarily imply that the KAI1 gene is a target for regulation by p53. Indeed, this situation has been shown for promoters of other genes originally suggested as targets for regulation by p53, for example, mouse MCK promoter. 34 Nevertheless, the balance of available data suggests that p53 is not a major determinant of KAI1 transcription, and that loss of KAI1 expression during tumour progression is unlikely to result from loss of p53 function.
